The Schizophrenia Cognition Rating Scale: An Interview-Based Assessment and Its Relationship to Cognition, Real-World Functioning, and Functional Capacity
2006/03/01 by Richard S.E. Keefe, Margaret Poe, Margaret P. Poe +3 · 28 citations
Medicine · Psychology · #Schizophrenia research and treatment #Dementia and Cognitive Impairment Research #Cognitive Functions and Memory
paper · doi:10.1176/appi.ajp.163.3.426
Abstract
OBJECTIVE: Interview-based measures of cognition may serve as potential coprimary measures in clinical trials of cognitive-enhancing drugs for schizophrenia. However, there is no such valid scale available. Interviews of patients and their clinicians are not valid in that they are unrelated to patients' levels of cognitive impairment as assessed by cognitive performance tests. This study describes the reliability and validity of a new interview-based assessment of cognition, the Schizophrenia Cognition Rating Scale (SCoRS), that involves interviews with patients and informants. METHOD: Sixty patients with schizophrenia were assessed with the SCoRS and three potential validators of an interview-based measure of cognition: cognitive performance, as measured by the Brief Assessment of Cognition in Schizophrenia (BACS); real-world functioning, as measured by the Independent Living Skills Inventory; and functional capacity, as measured by the University of California, San Diego, Performance-Based Skills Assessment (UPSA). RESULTS: The SCoRS global ratings were significantly correlated with composite scores of cognitive performance and functional capacity and with ratings of real-world functioning. Multiple regression analyses suggested that SCoRS global ratings predicted unique variance in real-world functioning beyond that predicted by the performance measures. CONCLUSIONS: An interview-based measure of cognition that included informant reports was related to cognitive performance as well as real-world functioning. Interview-based measures of cognition, such as the SCoRS, may be valid coprimary measures for clinical trials assessing cognitive change and may also aid clinicians desiring to assess patients' level of cognitive impairment.
Cited by
- Cognition as an outcome measure in schizophrenia
- Assessing the prevalence of cognitive impairment among Australians with schizophrenia: A systematic review
- The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?
- Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. [europepmc]
- Self-assessment of functional status in schizophrenia. [europepmc]
- Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. [europepmc]
- Performance-based measurement of functional disability in schizophrenia: a cross-national study in the United States and Sweden. [europepmc]
- The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition. [europepmc]
- A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. [europepmc]
- Assessing everyday functioning in schizophrenia: not all informants seem equally informative. [europepmc]
- The importance of measuring psychosocial functioning in schizophrenia. [europepmc]
- Quantifying clinical relevance in the treatment of schizophrenia. [europepmc]
- Self-assessment of functional ability in schizophrenia: milestone achievement and its relationship to accuracy of self-evaluation. [europepmc]
- Common and specific cognitive deficits in schizophrenia: relationships to function. [europepmc]
- Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. [europepmc]
- The effects of aging on insight into illness in schizophrenia: a review. [europepmc]
- Factors influencing self-assessment of cognition and functioning in schizophrenia: implications for treatment studies. [europepmc]
- Observable Social Cognition--A Rating Scale: an interview-based assessment for schizophrenia. [europepmc]
- Altered resting-state EEG source functional connectivity in schizophrenia: the effect of illness duration. [europepmc]
- Validation of a Computerized test of Functional Capacity. [europepmc]
- Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. [europepmc]
- Cognition, social cognition, and Self-assessment in schizophrenia: prediction of different elements of everyday functional outcomes. [europepmc]
- Autism symptoms, depression, and active social avoidance in schizophrenia: Association with self-reports and informant assessments of everyday functioning. [europepmc]
- Efficacy of Intensive Cerebellar Intermittent Theta Burst Stimulation (iCiTBS) in Treatment-Resistant Schizophrenia: a Randomized Placebo-Controlled Study. [europepmc]
- The clinical characterization of the patient with primary psychosis aimed at personalization of management. [europepmc]
- Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions. [europepmc]
- Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art. [europepmc]
- European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia. [europepmc]
Related